Earnings summaries and quarterly performance for RAPT Therapeutics.
Executive leadership at RAPT Therapeutics.
Board of directors at RAPT Therapeutics.
Research analysts covering RAPT Therapeutics.
Recent press releases and 8-K filings for RAPT.
RAPT Therapeutics to be Acquired by GSK
RAPT
M&A
Takeover Bid
- GSK has entered into a definitive agreement to acquire RAPT Therapeutics.
- Under the terms of the agreement, GSK will pay RAPT Therapeutics shareholders $58.00 per share in cash, representing an estimated aggregate equity value of $2.2 billion.
- The acquisition includes ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody in phase IIb clinical development for prophylactic protection against food allergens.
- The transaction is expected to close in the first quarter of 2026.
7 days ago
RAPT Therapeutics to be Acquired by GSK
RAPT
M&A
Takeover Bid
New Projects/Investments
- GSK has agreed to acquire RAPT Therapeutics for approximately $2.2 billion, offering $58 per share (roughly $1.9 billion upfront in cash).
- The acquisition strengthens GSK's respiratory, immunology, and inflammation pipeline by providing global rights (excluding Greater China) to ozureprubart, a long-acting anti-IgE monoclonal antibody in Phase IIb development for food allergies.
- Ozureprubart is designed for roughly 12-weekly dosing, which could significantly reduce injection frequency compared to current anti-IgE therapies and expand treatment eligibility.
- Phase IIb data for ozureprubart are anticipated in 2027, and the deal is expected to close in the first quarter of 2026.
7 days ago
RAPT Therapeutics Provides Update on Ozureprobart Clinical Development and Financial Position
RAPT
New Projects/Investments
Guidance Update
- RAPT Therapeutics' lead asset, Ozureprobart, a next-generation anti-IgE, targets significant market opportunities in food allergy (estimated >$40 billion) and chronic spontaneous urticaria (CSU) (estimated >$5 billion) in the United States.
- The company reported positive Phase 2 data for Ozureprobart in CSU, demonstrating 16-week durability and numerically superior efficacy compared to Omalazumab, and plans to initiate a Phase 3 study in CSU before the end of 2026.
- The Phase 2b food allergy study (PRESTIGE) has been initiated, with top-line data anticipated in the first half of 2027. Ozureprobart aims to offer less frequent dosing (every 8 or 12 weeks) and broader efficacy for patients, including those with high IgE/weight currently ineligible for Omalazumab.
- RAPT Therapeutics is well-funded, having completed a $265 million follow-on offering in 2025, extending its cash runway to mid-2028 through multiple clinical milestones.
Jan 14, 2026, 10:15 PM
RAPT Therapeutics provides update on Ozureprobart clinical development and financial outlook
RAPT
New Projects/Investments
Guidance Update
Board Change
- RAPT Therapeutics is advancing Ozureprobart, a next-generation anti-IgE, for food allergy and chronic spontaneous urticaria (CSU), targeting U.S. markets estimated at over $40 billion and $5 billion respectively.
- The company plans to initiate a Phase 3 study for Ozureprobart in CSU before the end of 2026, following positive Phase 2 data showing 16-week durability and a best-in-class profile.
- Top-line data from the Phase 2b food allergy study for Ozureprobart is expected in the first half of 2027.
- RAPT Therapeutics is well-funded, with a $265 million follow-on offering extending its cash runway to mid-2028, covering multiple clinical milestones.
- The company strengthened its leadership in 2025 by adding Lori Lyons-Williams as Board Chair, along with Scott Braunstein, MD, and Ashley Dombkowski to its board of directors.
Jan 14, 2026, 10:15 PM
RAPT Therapeutics Updates on Ozureprobart Clinical Development and Financial Outlook
RAPT
Product Launch
New Projects/Investments
Guidance Update
- RAPT Therapeutics is advancing Ozureprobart, a next-generation anti-IgE antibody designed for less frequent dosing and broader efficacy compared to Omalazumab, targeting significant market opportunities in food allergy (>$40 billion in the US) and chronic spontaneous urticaria (CSU) (>$5 billion in the US).
- The company initiated its Phase 2b food allergy study (PRESTIGE) in late October 2025, with top-line data expected in the first half of 2027.
- Following positive Phase 2 results in CSU, RAPT plans to initiate its own Phase 3 study in CSU before the end of 2026.
- RAPT is well-funded, with a cash runway projected through multiple clinical milestones, including the phase 2b food allergy readout, extending to mid-2028, supported by a $265 million follow-on offering.
Jan 14, 2026, 10:15 PM
RAPT Therapeutics Presents Corporate Strategy and Clinical Milestones at J.P. Morgan Healthcare Conference
RAPT
New Projects/Investments
Guidance Update
Management Change
- RAPT Therapeutics, Inc. presented its corporate strategy and pipeline at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.
- The company's lead product candidate, Ozureprubart (RPT904), a next-generation anti-IgE antibody, demonstrated positive Phase 2 data in Chronic Spontaneous Urticaria (CSU) with 16-week durability and is slated for Phase 3 initiation in 2H 2026.
- RAPT has also initiated a Phase 2b Food Allergy (FA) trial for Ozureprubart, with topline data expected in 1H 2027.
- Ozureprubart is positioned as a potential bio-better to omalizumab, offering advantages such as less frequent dosing (Q8/12W) and the ability to treat patients currently excluded from omalizumab's label, with payers supporting a price premium up to 15%.
- The company's cash runway is projected to extend through mid-2028, covering multiple clinical milestones, following a $265M follow-on offering.
Jan 14, 2026, 1:00 PM
Rapport Therapeutics Accelerates RAP-219 Phase 3 Program and Expands Epilepsy Portfolio
RAPT
New Projects/Investments
Guidance Update
- Rapport Therapeutics plans to initiate its RAP-219 Phase 3 program for focal onset seizures (FOS) in the second quarter of 2026, accelerating from previous guidance of Q3 2026, with a potential >$2 billion commercial opportunity in the U.S. if approved.
- The company is expanding its epilepsy portfolio with a new program in primary generalized tonic-clonic seizures (PGTCS), planning to initiate a Phase 3 trial of RAP-219 in PGTCS in the first half of 2027.
- Other pipeline updates include continued progress in the Phase 2 bipolar mania trial (topline results expected H1 2027), initiation of IND-enabling activities for a long-acting injectable in Q1 2026, and deferral of investment in the RAP-219 diabetic peripheral neuropathic pain (DPNP) program despite the clinical hold being lifted.
- As of the end of the third quarter, Rapport Therapeutics held $513.0 million in cash, cash equivalents, and short-term investments, which is expected to fund operations into the second half of 2029.
Jan 7, 2026, 12:00 PM
RAPT Therapeutics Updates on Ozureprubart (RPT-904) Clinical Development
RAPT
New Projects/Investments
Guidance Update
- Ozureprubart (RPT-904), a next-generation anti-IgE drug, is being developed by RAPT Therapeutics for food allergy, chronic spontaneous urticaria (CSU), and asthma, aiming for less frequent dosing and broader patient access compared to Xolair.
- A Chinese Phase 2 CSU study demonstrated that Ozureprubart at Q8 and Q12 week dosing provided comparable or numerically superior results to omalizumab (Xolair) in UAS7 scores, with durability extending up to 16 weeks and a favorable safety profile.
- RAPT plans to advance Ozureprubart into two Phase 3 pivotal studies for CSU, each enrolling 300-350 patients, with the primary endpoint being UAS7 at week 12.
- The Prestige study, a 100-patient placebo-controlled Phase 2 trial for food allergy, initiated in October, is evaluating Q8 and Q12 week dosing in adolescents and adults, with a primary endpoint at 24 weeks.
- Data from a PKPD study in asthma, conducted by partner Shanghai Jeyou Pharmaceutical, focusing on free IgE reduction, is expected by year-end.
Nov 13, 2025, 7:30 PM
RAPT Therapeutics Provides Update on Ozureprubart Clinical Development and Financials
RAPT
New Projects/Investments
Guidance Update
- RAPT Therapeutics' lead asset, ozureprubart (RPT-904), an anti-IgE, omalizumab biobetter, is being developed for food allergy and chronic spontaneous urticaria (CSU), targeting multi-billion dollar market opportunities.
- The company reported numerically superior efficacy for ozureprubart compared to omalizumab in a Phase 2 CSU trial across all endpoints and time points, even after a single dose out to week 16, with plans to initiate Phase 3 studies next year.
- A Phase 2b study for food allergy commenced at the end of October, with a readout anticipated in early 2027.
- RAPT's pro forma cash balance was $392 million at the end of Q3, providing a projected cash runway into mid-2028.
Nov 12, 2025, 7:40 PM
Remedy Plan Therapeutics Announces RPT1G Phase 1 Safety Data and IND Clearance
RAPT
Product Launch
New Projects/Investments
- RPT1G, a NAMPT inhibitor developed by Remedy Plan Therapeutics, demonstrated safety and good tolerability in a Phase 1 study in healthy volunteers at single and multiple ascending dose levels.
- The FDA has cleared Remedy Plan's Investigational New Drug (IND) application for RPT1G, allowing it to proceed with a Phase 1 study in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes/neoplasms (HR-MDS).
- Remedy Plan Therapeutics also received orphan drug designation for RPT1G in AML from the FDA.
Nov 12, 2025, 1:00 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more